JavaScript is NOT enabled !

Please enable JavaScript.

Article

PubMed

This record comes from PubMed

Radioimmunotherapy-augmented BEAM chemotherapy vs BEAM alone as the high-dose regimen for autologous stem cell transplantation (ASCT) in relapsed follicular lymphoma (FL): a retrospective study of the EBMT Lymphoma Working Party

Bone marrow transplantation. 2017 Aug ; 52 (8) : 1120-1125. [epub] 20170522

Bone Marrow Transplant
ISSN 1476-5365 | 0268-3369
Source

Language English Country Great Britain, England Media print-electronic

Document type Comparative Study, Journal Article

Persistent link https://www.medvik.cz/link/pmid28530668

PubMed 28530668
DOI 10.1038/bmt.2017.88
PII: bmt201788
Knihovny.cz E-resources

MeSH
Survival Analysis MeSH
Transplantation, Autologous MeSH
Cytarabine therapeutic use MeSH
Adult MeSH
Etoposide therapeutic use MeSH
Lymphoma, Follicular mortality therapy MeSH
Carmustine therapeutic use MeSH
Combined Modality Therapy methods MeSH
Middle Aged MeSH
Humans MeSH
Melphalan therapeutic use MeSH
Young Adult MeSH
Antineoplastic Combined Chemotherapy Protocols therapeutic use MeSH
Radioimmunotherapy methods MeSH
Retrospective Studies MeSH
Rituximab therapeutic use MeSH
Aged MeSH
Case-Control Studies MeSH
Hematopoietic Stem Cell Transplantation methods mortality MeSH
Check Tag
Adult MeSH
Middle Aged MeSH
Humans MeSH
Young Adult MeSH
Male MeSH
Aged MeSH
Female MeSH
Publication type
Journal Article MeSH
Comparative Study MeSH
Names of Substances
Cytarabine MeSH
Etoposide MeSH
Carmustine MeSH
Melphalan MeSH
Rituximab MeSH

Relapse remains the most common cause of treatment failure in patients receiving autologous stem cell transplantation (ASCT) for follicular lymphoma (FL). The aim of this study was to evaluate the effect of adding radioimmunotherapy or rituximab (R) to BEAM (carmustine, etoposide, ara-c, melphalan) high-dose therapy for ASCT in patients with relapsed FL. Using the European Society for Blood and Marrow Transplantation registry, we conducted a cohort comparison of BEAM (n=1973), Zevalin-BEAM (Z-BEAM) (n=207) and R-BEAM (n=179) and also a matched-cohort analysis of BEAM vs Z-BEAM including 282 and 154 patients, respectively. BEAM, Z-BEAM and R-BEAM groups were well balanced for age, time from diagnosis to ASCT and disease status at ASCT. The cumulative incidences of relapse (IR) at 2 years were 34, 34 and 32% for Z-BEAM, R-BEAM and BEAM, respectively. By multivariate analysis, there were no significant differences with Z-BEAM or R-BEAM compared with BEAM for IR, non-relapse mortality, event-free survival or overall survival. With the caveat that the limitations of registry analyses have to be taken into account, this study does not support adding radioimmunotherapy or R to BEAM in ASCT for relapsed FL. However, we cannot rule out the existence a particular subset of patients who could benefit from Z-BEAM conditioning that cannot be identified in our series, and this should be tested in a randomized trial.

Addenbrookes Hospital Cambridge UK

Azienda Ospedaliera Papa Giovanni XXIII Bergamo Italy

Bologna University S Orsola Malpighi Hospital Bologna Italy

Centre for Clinical Haematology Birmingham UK

Centre Henri Becquerel Rouen France

Centre Hospitalier Saint Louis Paris France

Centre Leon Berard Lyon France

Charles University Hospital Prague Czech Republic

CHU Amiens France

CHU Clermont Ferrand France

CHU Lapeyronie Montpellier France

CHU Nantes France